Compare TRVI & ATEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRVI | ATEC |
|---|---|---|
| Founded | 2011 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.5B |
| IPO Year | 2019 | 2006 |
| Metric | TRVI | ATEC |
|---|---|---|
| Price | $12.50 | $10.92 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 14 |
| Target Price | ★ $28.18 | $15.79 |
| AVG Volume (30 Days) | ★ 2.5M | 2.0M |
| Earning Date | 11-12-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.91 | 15.04 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $101,739,000.00 |
| Revenue This Year | N/A | $15.43 |
| Revenue Next Year | N/A | $15.24 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.82 | $6.82 |
| 52 Week High | $20.22 | $23.29 |
| Indicator | TRVI | ATEC |
|---|---|---|
| Relative Strength Index (RSI) | 36.03 | 55.19 |
| Support Level | $11.70 | $10.61 |
| Resistance Level | $13.55 | $11.03 |
| Average True Range (ATR) | 0.66 | 0.48 |
| MACD | 0.13 | 0.02 |
| Stochastic Oscillator | 44.81 | 57.33 |
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.
Alphatec Holdings Inc is a medical technology company focused on the designing, development, and advancement of products for the surgical treatment of spinal disorders associated with disease and degeneration, congenital deformities, and trauma. The company's spine approach technologies include Posterior Cervical Fusion, Anterior Cervical Discectomy and Fusion, Lateral Interbody Fusion, and Posterior Lumbar Interbody Fusion among others. Its procedural offerings are designed to address the underlying causes of spinal pathology by advancing the three fundamental objectives of spine surgery: (1) decompression of neural elements, (2) stabilization of spinal segments, and (3) restoration and maintenance of proper spinal alignment.